Bybit lists MRNA (TradFi stock perpetual) with up to 25x leverage.
DeFi & Yields ·
Bybit has listed the MRNAUSDT TradFi Perpetual Contract, allowing traders to access leveraged exposure to Moderna's stock price movements with up to 25x leverage. Trading opened on August 20, 2026, and the contract is available through several automated trading strategies including Futures Grid, Futures Martingale, and Futures Combo.
The product is a synthetic derivative instrument referencing the underlying equity price rather than conferring ownership of the stock itself. Traders therefore have no claim to dividends, voting rights, or distributions tied to the underlying asset. Bybit notes that contract prices may diverge from actual stock prices and reserves the right to adjust leverage, margin requirements, and other parameters at any time.
The platform emphasizes that trading carries substantial risk, including potential total loss of margin and additional losses from leverage. Corporate actions affecting Moderna's stock—such as stock splits, mergers, or delistings—may trigger contract adjustments, price changes, or termination. Availability varies by jurisdiction and Bybit may restrict or suspend access in compliance with local regulations.